Selected research
Market Structure
Global Rasagiline Tablet Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Rasagiline Tablet market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Rasagiline Tablet is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Rasagiline Tablet is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Rasagiline Tablet is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Rasagiline Tablet is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Rasagiline Tablet include Takeda Pharmaceutical, Teva Pharmaceutical, Sun Pharmaceutical, Sandoz, Mylan, Taj Pharma, Orchid Pharma, Natco Pharma and Lundbeck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Rasagiline Tablet market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Rasagiline Tablet and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Rasagiline Tablet sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Rasagiline Tablet market size, projected growth trends, production technologies, key applications, and end-use industries.
Rasagiline Tablet Segment by Company
Takeda Pharmaceutical
Teva Pharmaceutical
Sun Pharmaceutical
Sandoz
Mylan
Taj Pharma
Orchid Pharma
Natco Pharma
Lundbeck
Intas Pharmaceuticals
Apotex
Alkem Laboratories
Ajanta Pharma
Rasagiline Tablet Segment by Type
0.5 mg/Pcs
1 mg/Pcs
Rasagiline Tablet Segment by Application
40-65 Years Old
Under 40 Years Old
Above 65 Years Old
Rasagiline Tablet Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rasagiline Tablet market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rasagiline Tablet and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rasagiline Tablet.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Rasagiline Tablet market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rasagiline Tablet manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Rasagiline Tablet in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Rasagiline Tablet in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 0.5 mg/Pcs
- 1 mg/Pcs
Applications
- 40-65 Years Old
- Under 40 Years Old
- Above 65 Years Old
Companies covered
- Takeda Pharmaceutical
- Teva Pharmaceutical
- Sun Pharmaceutical
- Sandoz
- Mylan
- Taj Pharma
- Orchid Pharma
- Natco Pharma
- Lundbeck
- Intas Pharmaceuticals
- Apotex
- Alkem Laboratories
- Ajanta Pharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Rasagiline Tablet Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Rasagiline Tablet Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Rasagiline Tablet Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Rasagiline Tablet Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Rasagiline Tablet Market Dynamics
- 2.1 Rasagiline Tablet Industry Trends
- 2.2 Rasagiline Tablet Industry Drivers
- 2.3 Rasagiline Tablet Industry Opportunities and Challenges
- 2.4 Rasagiline Tablet Industry Restraints
3 Rasagiline Tablet Market by Manufacturers
- 3.1 Global Rasagiline Tablet Revenue by Manufacturers (2021-2026)
- 3.2 Global Rasagiline Tablet Sales by Manufacturers (2021-2026)
- 3.3 Global Rasagiline Tablet Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Rasagiline Tablet Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Rasagiline Tablet Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Rasagiline Tablet Manufacturers, Product Type & Application
- 3.7 Global Rasagiline Tablet Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Rasagiline Tablet Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Rasagiline Tablet Players Market Share by Revenue in 2025
- 3.8.3 2025 Rasagiline Tablet Tier 1, Tier 2, and Tier 3
4 Rasagiline Tablet Market by Type
- 4.1 Rasagiline Tablet Type Introduction
- 4.1.1 0.5 mg/Pcs
- 4.1.2 1 mg/Pcs
- 4.2 Global Rasagiline Tablet Sales by Type
- 4.2.1 Global Rasagiline Tablet Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Rasagiline Tablet Sales by Type (2021-2032)
- 4.2.3 Global Rasagiline Tablet Sales Market Share by Type (2021-2032)
- 4.3 Global Rasagiline Tablet Revenue by Type
- 4.3.1 Global Rasagiline Tablet Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Rasagiline Tablet Revenue by Type (2021-2032)
- 4.3.3 Global Rasagiline Tablet Revenue Market Share by Type (2021-2032)
5 Rasagiline Tablet Market by Application
- 5.1 Rasagiline Tablet Application Introduction
- 5.1.1 40-65 Years Old
- 5.1.2 Under 40 Years Old
- 5.1.3 Above 65 Years Old
- 5.2 Global Rasagiline Tablet Sales by Application
- 5.2.1 Global Rasagiline Tablet Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Rasagiline Tablet Sales by Application (2021-2032)
- 5.2.3 Global Rasagiline Tablet Sales Market Share by Application (2021-2032)
- 5.3 Global Rasagiline Tablet Revenue by Application
- 5.3.1 Global Rasagiline Tablet Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Rasagiline Tablet Revenue by Application (2021-2032)
- 5.3.3 Global Rasagiline Tablet Revenue Market Share by Application (2021-2032)
6 Global Rasagiline Tablet Sales by Region
- 6.1 Global Rasagiline Tablet Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Rasagiline Tablet Sales by Region (2021-2032)
- 6.2.1 Global Rasagiline Tablet Sales by Region (2021-2026)
- 6.2.2 Global Rasagiline Tablet Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Rasagiline Tablet Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Rasagiline Tablet Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Rasagiline Tablet Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Rasagiline Tablet Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Rasagiline Tablet Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Rasagiline Tablet Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Rasagiline Tablet Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Rasagiline Tablet Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Rasagiline Tablet Revenue by Region
- 7.1 Global Rasagiline Tablet Revenue by Region
- 7.1.1 Global Rasagiline Tablet Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Rasagiline Tablet Revenue by Region (2021-2026)
- 7.1.3 Global Rasagiline Tablet Revenue by Region (2027-2032)
- 7.1.4 Global Rasagiline Tablet Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Rasagiline Tablet Revenue (2021-2032)
- 7.2.2 North America Rasagiline Tablet Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Rasagiline Tablet Revenue (2021-2032)
- 7.3.2 Europe Rasagiline Tablet Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Rasagiline Tablet Revenue (2021-2032)
- 7.4.2 Asia-Pacific Rasagiline Tablet Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Rasagiline Tablet Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Rasagiline Tablet Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Takeda Pharmaceutical
- 8.1.1 Takeda Pharmaceutical Company Information
- 8.1.2 Takeda Pharmaceutical Business Overview
- 8.1.3 Takeda Pharmaceutical Rasagiline Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Takeda Pharmaceutical Rasagiline Tablet Product Portfolio
- 8.1.5 Takeda Pharmaceutical Recent Developments
- 8.2 Teva Pharmaceutical
- 8.2.1 Teva Pharmaceutical Company Information
- 8.2.2 Teva Pharmaceutical Business Overview
- 8.2.3 Teva Pharmaceutical Rasagiline Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Teva Pharmaceutical Rasagiline Tablet Product Portfolio
- 8.2.5 Teva Pharmaceutical Recent Developments
- 8.3 Sun Pharmaceutical
- 8.3.1 Sun Pharmaceutical Company Information
- 8.3.2 Sun Pharmaceutical Business Overview
- 8.3.3 Sun Pharmaceutical Rasagiline Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Sun Pharmaceutical Rasagiline Tablet Product Portfolio
- 8.3.5 Sun Pharmaceutical Recent Developments
- 8.4 Sandoz
- 8.4.1 Sandoz Company Information
- 8.4.2 Sandoz Business Overview
- 8.4.3 Sandoz Rasagiline Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Sandoz Rasagiline Tablet Product Portfolio
- 8.4.5 Sandoz Recent Developments
- 8.5 Mylan
- 8.5.1 Mylan Company Information
- 8.5.2 Mylan Business Overview
- 8.5.3 Mylan Rasagiline Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Mylan Rasagiline Tablet Product Portfolio
- 8.5.5 Mylan Recent Developments
- 8.6 Taj Pharma
- 8.6.1 Taj Pharma Company Information
- 8.6.2 Taj Pharma Business Overview
- 8.6.3 Taj Pharma Rasagiline Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Taj Pharma Rasagiline Tablet Product Portfolio
- 8.6.5 Taj Pharma Recent Developments
- 8.7 Orchid Pharma
- 8.7.1 Orchid Pharma Company Information
- 8.7.2 Orchid Pharma Business Overview
- 8.7.3 Orchid Pharma Rasagiline Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Orchid Pharma Rasagiline Tablet Product Portfolio
- 8.7.5 Orchid Pharma Recent Developments
- 8.8 Natco Pharma
- 8.8.1 Natco Pharma Company Information
- 8.8.2 Natco Pharma Business Overview
- 8.8.3 Natco Pharma Rasagiline Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Natco Pharma Rasagiline Tablet Product Portfolio
- 8.8.5 Natco Pharma Recent Developments
- 8.9 Lundbeck
- 8.9.1 Lundbeck Company Information
- 8.9.2 Lundbeck Business Overview
- 8.9.3 Lundbeck Rasagiline Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Lundbeck Rasagiline Tablet Product Portfolio
- 8.9.5 Lundbeck Recent Developments
- 8.10 Intas Pharmaceuticals
- 8.10.1 Intas Pharmaceuticals Company Information
- 8.10.2 Intas Pharmaceuticals Business Overview
- 8.10.3 Intas Pharmaceuticals Rasagiline Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Intas Pharmaceuticals Rasagiline Tablet Product Portfolio
- 8.10.5 Intas Pharmaceuticals Recent Developments
- 8.11 Apotex
- 8.11.1 Apotex Company Information
- 8.11.2 Apotex Business Overview
- 8.11.3 Apotex Rasagiline Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Apotex Rasagiline Tablet Product Portfolio
- 8.11.5 Apotex Recent Developments
- 8.12 Alkem Laboratories
- 8.12.1 Alkem Laboratories Company Information
- 8.12.2 Alkem Laboratories Business Overview
- 8.12.3 Alkem Laboratories Rasagiline Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Alkem Laboratories Rasagiline Tablet Product Portfolio
- 8.12.5 Alkem Laboratories Recent Developments
- 8.13 Ajanta Pharma
- 8.13.1 Ajanta Pharma Company Information
- 8.13.2 Ajanta Pharma Business Overview
- 8.13.3 Ajanta Pharma Rasagiline Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Ajanta Pharma Rasagiline Tablet Product Portfolio
- 8.13.5 Ajanta Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Rasagiline Tablet Value Chain Analysis
- 9.1.1 Rasagiline Tablet Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Rasagiline Tablet Production Mode & Process
- 9.2 Rasagiline Tablet Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Rasagiline Tablet Distributors
- 9.2.3 Rasagiline Tablet Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst